Stay up-to-date with the Dr Reddys Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Dr Reddy’s Laboratories has signed a license deal with Shanghai Henlius Biotech to develop and market HLX15, an investigational cancer drug. Henlius will handle development and manufacturing, ...

Dr. Reddy's Laboratories Ltd. closed 12.96% short of its 52-week high of 1,420.20 rupees, which the company reached on August ...

Dr Reddy’s Laboratories ( ($RDY) ) has shared an update. On February 4, 2025, Dr. Reddy’s Laboratories announced its participation in an investor ...

An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...

Dr. Reddy's Laboratories Ltd. closed 14.12% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Dr Reddy's Laboratories Stock Price: Dr Reddy's shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE). Listen to Story ...

Shares of Dr Reddy's Laboratories fell by 5% as the company's third-quarter profit rise failed to impress investors. The ...